Leading Canadian Healthcare Services Provider Selects Crescita as Exclusive Manufacturing Partner under 5-Year Agreement
2024年7月19日 - 8:30PM
ビジネスワイヤ(英語)
Crescita Therapeutics Inc. (TSX: CTX and OTC US:
CRRTF) (“Crescita” or the “Company”), a
growth-oriented, innovation-driven Canadian commercial dermatology
company with in-house R&D and manufacturing capabilities, today
announced that it has signed an exclusive Manufacturing and Supply
Agreement (the “Agreement”) with a leading Canadian diversified
healthcare services provider (the “Client”) to supply various
sanitary products, including hand sanitizer, hand soap, and hand
lotions (together the “Products”), for onward distribution to a
network of publicly funded healthcare organizations, represented by
a buying group (the “Buying Group” and the “Buying Group
Members”).
With an initial term of five years and a three-year renewal
option exercisable by the Buying Group, the Agreement does not
provide for minimum order quantities. However, based on the
forecasted volumes, annual revenue under the Agreement may reach up
to $6.0 million by the end of the initial term. Crescita’s
manufacturing revenue will be contingent on the Client’s ability to
convert Buying Group Members from their existing solutions to its
new sanitizer dispensing solution. As its exclusive manufacturing
partner, Crescita will support the Client in developing the public
sector healthcare market for the Products through competitive
bidding processes with other buying groups in Canada.
“We are very pleased to have been selected by the Client, a
prominent player in the Canadian pharmaceutical industry, as their
exclusive supplier for this multi-year, multi-jurisdiction project.
We believe that the strong partnership we have forged will pave the
way for future collaborations,” commented Serge Verreault,
President and CEO of Crescita.
About Crescita Therapeutics Inc. Crescita (TSX: CTX and
OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian
commercial dermatology company with in-house R&D and
manufacturing capabilities. The Company offers a portfolio of
high-quality, science-based non-prescription skincare products and
early to commercial stage prescription products. We also own
multiple proprietary transdermal delivery platforms that support
the development of patented formulations to facilitate the delivery
of active ingredients into or through the skin. For more
information visit, www.crescitatherapeutics.com.
Forward-looking Information All information in this press
release, other than statements of current and historical fact,
represent forward-looking information within the meaning of
applicable securities laws and is qualified by this cautionary
note. Forward-looking information can be identified by words such
as: “anticipate”, “intend”, “plan”, “goal”, “seek”, “believe”,
“aim”, “project”, “estimate”, “expect”, “strategy”, “future”,
“likely”, “may”, “should”, “will”, “forecast”, and similar
references to future periods. Forward-looking information in this
press release includes, but is not limited to statements with
respect to the forecasted volumes, revenues resulting from the
Agreement, the deployment of hand sanitizer dispensers within the
Buying Group Members, the development of a public sector healthcare
market for the Products and future collaborations with the
Client.
Forward-looking information is neither historical fact nor an
assurance of future performance. Instead, it is based only on
current beliefs, expectations, and assumptions regarding the future
of the Company’s business, future plans and strategies,
projections, anticipated events and trends, the economy and other
future conditions.
Because forward-looking information relates to the future, it is
subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict and many of which are
outside of the Company’s control.
Actual results may differ materially from those indicated in
forward-looking information. Therefore, you should not unduly rely
on any forward-looking information. Important factors and risks
that could cause actual results to differ materially from those
indicated in forward-looking information include, among others:
- economic and market conditions including factors impacting
global supply chains such as pandemics and geopolitical conflicts
and tensions;
- the impact of inflation and fluctuating interest rates;
- the degree or lack of market acceptance of the Products by the
Buying Group Members;
- reliance on third parties for marketing and distribution;
- the impact of changing conditions in the regulatory environment
and product development processes;
- manufacturing and supply risks;
- the Company’s ability to meet its contractual obligations;
- the impact of product liability matters;
- the impact of litigation involving the Company and/or the
Products;
- the impact of changes in relationships with the Client;
- the failure to renew the Agreement following the initial
term;
- the failure to achieve forecasted volumes;
- developments and changes in applicable laws and
regulations;
- the failure to achieve expected order quantities and/or revenue
under the Agreement;
- the Client’s failure to deploy the new hand sanitizer
dispensing solutions within the facilities of the Buying Group
Members; and
- the failure to further develop the public sector healthcare
market for the Products and be successful in the competitive
bidding process.
As a result of the foregoing and other factors, no assurance can
be given that future results, levels of activity or achievements
indicated in any forward-looking information will actually be
achieved. Any forward-looking information in this press release is
based only on information currently available to management and
speaks only as of the date on which it is provided. Except as
required by applicable securities laws, Crescita undertakes no
obligation to publicly update any forward-looking information,
whether written or oral, that may be provided from time to time,
whether as a result of new information, future developments or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240719359002/en/
FOR MORE INFORMATION: Investor Relations Linda Kisa, CPA,
CA Vice-President, Reporting and Corporate Affairs Email:
lkisa@crescitatx.com
Crescita Therapeutics (TSX:CTX)
過去 株価チャート
から 10 2024 まで 11 2024
Crescita Therapeutics (TSX:CTX)
過去 株価チャート
から 11 2023 まで 11 2024